Description:
This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a single agent and in
combination with budigalimab (ABBV-181) in participants with relapsed or refractory small
cell lung cancer (SCLC). The study consists of 4 parts: Part A is a single-agent ABBV-011
dose regimen finding cohort; followed by Part B, a single-agent ABBV-011 dose expansion
cohort; and then Part C, an ABBV-011 and budigalimab (ABBV-181) combination escalation and
expansion cohort; Part D, single-agent ABBV-011 dose-evaluating cohort for Japan.
Title
- Brief Title: A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
- Official Title: A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Clinical Trial IDs
- ORG STUDY ID:
M17-327
- NCT ID:
NCT03639194
Conditions
Interventions
Drug | Synonyms | Arms |
---|
ABBV-011 | SC-011 | Part A: ABBV-011 Dose Escalation |
Budigalimab | ABBV-181 | Part C: ABBV-011 + Budigalimab Escalation and Expansion |
Purpose
This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a single agent and in
combination with budigalimab (ABBV-181) in participants with relapsed or refractory small
cell lung cancer (SCLC). The study consists of 4 parts: Part A is a single-agent ABBV-011
dose regimen finding cohort; followed by Part B, a single-agent ABBV-011 dose expansion
cohort; and then Part C, an ABBV-011 and budigalimab (ABBV-181) combination escalation and
expansion cohort; Part D, single-agent ABBV-011 dose-evaluating cohort for Japan.
Trial Arms
Name | Type | Description | Interventions |
---|
Part A: ABBV-011 Dose Escalation | Experimental | ABBV-011 via intravenous administration at various doses and dosing regimens until the maximum tolerated dose and/or the recommended Part B dose(s) is declared. | |
Part B: ABBV-011 Dose Expansion | Experimental | ABBV-011 via intravenous administration at dose regimen(s) that will not exceed the maximum tolerated dose determined in Part A. | |
Part C: ABBV-011 + Budigalimab Escalation and Expansion | Experimental | ABBV-011 via intravenous administration at various doses and dosing regimens starting at least 1 dose level below the recommended single-agent dose of ABBV-011 for Part B plus Budigalimab via intravenous administration at fixed doses and various dosing regimens. | |
Part D: ABBV-011 Dose Evaluation for Japan | Experimental | ABBV-011 via intravenous administration will be administered every 3 weeks (Q3wk), on Day 1 of each 21-day cycle or alternate dosing regimens. | |
Eligibility Criteria
Inclusion Criteria:
- Must have histologically or cytologically confirmed small cell lung cancer (SCLC) that
is relapsed or refractory following at least 1 prior platinum-based systemic
chemotherapy, but no more than 3 total prior lines of therapy, and with no curative
therapy available.
- Measurable disease, defined as at least 1 tumor lesion greater than or equal to 10 mm
in the longest diameter or a lymph node greater than or equal to 15 mm in short axis
measurement assessed by computed tomography (CT) scan, according to Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Minimum life expectancy of at least 12 weeks.
- Recovery to at least Grade 1 of any clinically significant toxicity (excluding
alopecia) prior to initiation of study drug administration.
- Adequate hematologic, hepatic, neurologic, and renal function.
- All participants in Part B and Part C will be required to have tumor tissue that tests
positive for target expression.
- Sponsor may elect for confirmed SCLC tumor tissue to test positive for target
expression for Parts A and D participants as well.
- Last dose of any prior anticancer therapy >= 4 weeks before the first dose of study
drug.
Additional Inclusion Criteria for Study Part B and Part C:
- SCLC tumor tissue that tests positive for seizure-related homolog 6 (SEZ6) by
immunohistochemistry (IHC).
Exclusion Criteria:
- History of confirmed or suspected liver cirrhosis, hepatic veno-occlusive disease
(VOD), sinusoidal obstruction syndrome (SOS), alcohol dependence, or ongoing excessive
alcohol use.
- Prior history of allogeneic or autologous stem cell transplantation.
- Documented history of stroke or clinically significant cardiac disease as described in
the protocol within 6 months prior to the first dose of study drug.
- History of cardiac conduction abnormalities as described in the protocol.
- Recent or ongoing serious infection, as described in the protocol.
- Active SARS-CoV-2 infection.
- Prior or concomitant malignancies with some exceptions, as described in the protocol.
- Any significant medical or psychiatric condition, including any suggested by Screening
laboratory findings, that in the opinion of the Investigator or Sponsor may place the
participant at undue risk from the study treatment, interfere with interpretation of
study results, or compromise ability to comply with protocol requirements.
Additional Exclusion Criteria for Part C:
- History of inflammatory bowel disease.
- Peripheral neuropathy Grade 2 with pain, or Grade 3 or higher.
- Body weight less than 35 kilograms.
- Active pneumonitis or interstitial lung disease (ILD) or a history of pneumonitis/ILD
requiring treatment with steroids.
- Participants previously treated with an anti PD-1/PD-L1 targeting agent must meet
additional criteria described in the protocol.
- Participant is judged by the Investigator to have evidence of ongoing hemolysis.
- Immunosuppressive use with exceptions as per protocol.
- Participants who have received a live vaccine within 30 days of start of study
treatment.
- Active autoimmune disease with exceptions as indicated in the protocol.
- History of primary immunodeficiency, solid organ transplantation, or previous clinical
diagnosis of tuberculosis.
- Participants with a history of Stevens-Johnson syndrome (SJS), toxic epidermal
necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS).
Additional exclusion criteria for Part D (Japanese participants):
- Participants with a history of hypersensitivity to the ingredients of ABBV-011 will be
excluded.
- Participants with a history of interstitial lung disease (pneumonitis) or current
interstitial lung disease (pneumonitis).
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Number of Participants With Adverse Events |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. |
Secondary Outcome Measures
Measure: | Maximum Serum Concentration (Cmax) of ABBV-011 |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Maximum Serum Concentration (Cmax) of ABBV-011. |
Measure: | Area Under the Serum Concentration-Time Curve (AUCinf) of ABBV-011 |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Area under the serum concentration-time curve within a dosing interval of ABBV-011. |
Measure: | Area Under the Serum Concentration-Time Curve from 0 to Last Measurable Concentration (AUC0-t) of ABBV-011 |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Area under the serum concentration-time curve from 0 to last measurable concentration (AUC0-t) of ABBV-011. |
Measure: | Time to Maximum Serum Concentration (Tmax) of ABBV-011 |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Time to maximum serum concentration (Tmax) of ABBV-011. |
Measure: | Observed Serum Concentration at Trough (Ctrough) of ABBV-011 |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Observed serum concentration at trough (Ctrough) of ABBV-011. |
Measure: | Apparent Terminal Half-Life (T1/2) of ABBV-011 |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Apparent terminal half-life (T1/2) of ABBV-011. |
Measure: | Accumulation Ratio of ABBV-011 |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Accumulation ratio of ABBV-011. |
Measure: | Serum Clearance (CL) of ABBV-011 |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Serum clearance of ABBV011. |
Measure: | Steady State Volume of Distribution (Vss) of ABBV-011 |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Steady state volume of distribution (Vss) of ABBV-011. |
Measure: | Incidence of Antidrug Antibodies (ADA) Against ABBV-011 or Budigalimab (ABBV-181) |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | Number of participants with incidence of ADAs against ABBV-011 or budigalimab will be assessed. |
Measure: | Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | ORR is defined as the percentage of participants with confirmed Complete Response (CR) or Partial Response (PR). |
Measure: | Clinical Benefit Rate (CBR) |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | CBR is defined as the percentage of participants with best overall response (confirmed or unconfirmed) of CR, PR or stable disease (SD). |
Measure: | Duration of Response (DOR) |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | DOR is defined as the time from the participant's initial objective response (CR or PR) to Progressive Disease (PD) or death due to any cause, whichever occurs first. |
Measure: | Duration of Clinical Benefit (DOCB) |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | (DOCB) is defined as the time from the participant's initial observation of clinical benefit (CR or PR or SD) to PD or death due to any cause, whichever occurs first. |
Measure: | Progression-Free Survival (PFS) |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | PFS time is defined as the time from the subject's first dose of study drug (Day 1) to either the subject's disease progression (PD) or death due to any cause, whichever occurs first. |
Measure: | Overall Survival (OS) |
Time Frame: | Up to approximately 5 years after the first participant receives first dose of study drug |
Safety Issue: | |
Description: | OS is defined as the time from the subject's first dose date to death due to any cause. |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | AbbVie |
Trial Keywords
- Cancer
- Small Cell Lung Cancer
- Small Cell Lung Carcinoma
Last Updated
August 5, 2021